ONCS BRAS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.45 BRL | -9.37% |
|
+24.58% | -42.69% |
| Sales 2024 * | 6.55B 1.27B | Sales 2025 * | 7.57B 1.47B | Capitalization | 3.79B 735M |
|---|---|---|---|---|---|
| Net income 2024 * | 326M 63.24M | Net income 2025 * | 495M 96.02M | EV / Sales 2024 * | 1.18 x |
| Net Debt 2024 * | 3.91B 759M | Net Debt 2025 * | 3.7B 717M | EV / Sales 2025 * | 0.99 x |
| P/E ratio 2024 * |
15.1
x | P/E ratio 2025 * |
8.71
x | Employees | - |
| Yield 2024 * |
2.82% | Yield 2025 * |
1.95% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on ONCS BRAS
| 1 day | -9.37% | ||
| 1 week | +24.58% | ||
| Current month | +1.22% | ||
| 1 month | +2.76% | ||
| 3 months | -26.75% | ||
| 6 months | -22.88% | ||
| Current year | -42.69% |
1 week
6.31
8.44
1 month
5.388.44
Current year
5.3812.95
1 year
5.3813.00
3 years
4.0319.62
5 years
4.0319.62
10 years
4.0319.62
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 55 | 10-01-09 | |
| Director of Finance/CFO | 44 | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | - | |
| Founder | 55 | 10-01-09 | |
| Director of Finance/CFO | 44 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +4.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 7.45 | -9.37% | 9,239,300 |
| 24-05-21 | 8.22 | +3.92% | 4,500,200 |
| 24-05-20 | 7.91 | +11.88% | 13,884,700 |
| 24-05-17 | 7.07 | +10.47% | 11,285,700 |
| 24-05-16 | 6.4 | +7.02% | 7,549,000 |
Delayed Quote Sao Paulo, May 22, 2024 at 04:11 pm EDT
More quotes
Oncoclinicas do Brasil Servicos Medicos SA is a Brazil-based company engaged in the outpatient medical services sector. The company provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The company holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Sector
-
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.45
BRL
Average target price
14.06
BRL
Spread / Average Target
+88.76%
EPS Revisions
- Stock Market
- Equities
- ONCO3 Stock
